Restasis

Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye syndrome treatment Voclosporin ophthalmic solution (VOS) -- 0.2 percent --...

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

Shares of Allergan plc Ordinary Shares (NYSE: AGN) continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years. The Analyst Argus' David Toung downgraded Allergan's stock rating from Buy to...

Allergan plc Ordinary Shares (NYSE: AGN) have seen heavy selling pressure throughout parts of 2017, but some analysts are encouraging investors to take advantage of the weakness. The Analyst Morgan Stanley's David Risinger upgraded Allergan's stock rating from Equal-weight to Overweight...

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. According to Imprimis, Restasis lacks generic competition despite a...

BTIG’s Timothy Chiang believes 2017 will be a year filled with volume-growing companies in focus. Chiang maintains a Buy rating on Shire PLC (ADR) (NASDAQ: SHPG), with a price target of $242. Superior Product The analyst believes outperformance in 2017 could be driven by “management...